Business Description
BeiGene Ltd
NAICS : 325412
SIC : 2834
ISIN : KYG1146Y1017
Share Class Description:
HKSE:06160: Ordinary SharesCompare
Compare
Traded in other countries / regions
06160.Hong Kong688235.ChinaBGNE.USA49B.GermanyB1GN34.BrazilBGNE.Mexico IPO Date
2018-08-08Description
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.63 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -1.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.55 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 85.3 | |||||
| 3-Year EBITDA Growth Rate | 18 | |||||
| 3-Year EPS without NRI Growth Rate | 24.3 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | -7.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 26.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.01 | |||||
| 9-Day RSI | 33.12 | |||||
| 14-Day RSI | 38.2 | |||||
| 6-1 Month Momentum % | -16.59 | |||||
| 12-1 Month Momentum % | -15.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.08 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.48 | |||||
| Days Inventory | 310.37 | |||||
| Days Sales Outstanding | 45.22 | |||||
| Days Payable | 262.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.5 | |||||
| Shareholder Yield % | -1.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.69 | |||||
| Operating Margin % | -39.74 | |||||
| Net Margin % | -28.39 | |||||
| FCF Margin % | -56.68 | |||||
| ROE % | -21.07 | |||||
| ROA % | -13.67 | |||||
| ROIC % | -51.16 | |||||
| ROC (Joel Greenblatt) % | -84.79 | |||||
| ROCE % | -26.08 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.43 | |||||
| PB Ratio | 4.44 | |||||
| Price-to-Tangible-Book | 4.51 | |||||
| EV-to-EBIT | -12.76 | |||||
| EV-to-Forward-EBIT | -16.94 | |||||
| EV-to-EBITDA | -13.94 | |||||
| EV-to-Forward-EBITDA | -15.22 | |||||
| EV-to-Revenue | 5.07 | |||||
| EV-to-Forward-Revenue | 4.3 | |||||
| EV-to-FCF | -8.95 | |||||
| Price-to-Net-Current-Asset-Value | 9.32 | |||||
| Price-to-Net-Cash | 30.68 | |||||
| Earnings Yield (Greenblatt) % | -7.84 | |||||
| FCF Yield % | -9.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeiGene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 21,613.93 | ||
| EPS (TTM) (HK$) | -4.614 | ||
| Beta | 0.6 | ||
| Volatility % | 39.9 | ||
| 14-Day RSI | 38.2 | ||
| 14-Day ATR (HK$) | 3.635513 | ||
| 20-Day SMA (HK$) | 92.81 | ||
| 12-1 Month Momentum % | -15.05 | ||
| 52-Week Range (HK$) | 75.45 - 139.9 | ||
| Shares Outstanding (Mil) | 1,374.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeiGene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeiGene Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BeiGene Ltd Frequently Asked Questions
What is BeiGene Ltd(HKSE:06160)'s stock price today?
The current price of HKSE:06160 is HK$86.20. The 52 week high of HKSE:06160 is HK$139.90 and 52 week low is HK$75.45.
When is next earnings date of BeiGene Ltd(HKSE:06160)?
The next earnings date of BeiGene Ltd(HKSE:06160) is 2024-08-02 Est..
Does BeiGene Ltd(HKSE:06160) pay dividends? If so, how much?
BeiGene Ltd(HKSE:06160) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers